| Primary |
| Rhesus Haemolytic Disease Of Newborn |
15.8% |
| Idiopathic Thrombocytopenic Purpura |
10.5% |
| Multiple Sclerosis |
10.5% |
| Pityriasis Lichenoides Et Varioliformis Acuta |
10.5% |
| Blood Disorder |
5.3% |
| Cranial Nerve Disorder |
5.3% |
| Delayed Haemolytic Transfusion Reaction |
5.3% |
| Guillain-barre Syndrome |
5.3% |
| Kawasaki's Disease |
5.3% |
| Myelitis Transverse |
5.3% |
| Pancytopenia |
5.3% |
| Pneumonia Measles |
5.3% |
| Polyneuropathy In Malignant Disease |
5.3% |
| Worms |
5.3% |
|
| Necrotising Colitis |
15.8% |
| Maternal Exposure During Pregnancy |
10.5% |
| Off Label Use |
10.5% |
| Drug Ineffective |
5.3% |
| Drug Ineffective For Unapproved Indication |
5.3% |
| Ecchymosis |
5.3% |
| No Therapeutic Response |
5.3% |
| Pharyngeal Erythema |
5.3% |
| Pulmonary Mass |
5.3% |
| Respiratory Disorder |
5.3% |
| Respiratory Failure |
5.3% |
| Respiratory Muscle Weakness |
5.3% |
| Reticulocyte Count Increased |
5.3% |
| Skin Exfoliation |
5.3% |
| Stomatitis |
5.3% |
|
| Secondary |
| Kawasaki's Disease |
10.3% |
| Non-hodgkin's Lymphoma |
10.3% |
| Immunosuppression |
9.0% |
| Product Used For Unknown Indication |
9.0% |
| Immune Thrombocytopenic Purpura |
7.7% |
| Transplant Rejection |
6.5% |
| Lupus Nephritis |
5.2% |
| T-cell Lymphoma |
5.2% |
| Foetal Exposure During Pregnancy |
3.9% |
| Glycogen Storage Disease Type Ii |
3.9% |
| Mycobacterial Infection |
3.9% |
| Polymyositis |
3.9% |
| Acute Lymphocytic Leukaemia |
3.2% |
| Malignant Atrophic Papulosis |
3.2% |
| Urticaria Chronic |
3.2% |
| Acute Myeloid Leukaemia |
2.6% |
| Dermatomyositis |
2.6% |
| Multiple Sclerosis |
2.6% |
| Cytomegalovirus Viraemia |
1.9% |
| Immunomodulatory Therapy |
1.9% |
|
| Bronchopulmonary Aspergillosis |
8.0% |
| Progressive Multifocal Leukoencephalopathy |
8.0% |
| Respiratory Failure |
8.0% |
| Thrombocytopenia |
8.0% |
| Thrombosis |
8.0% |
| Alopecia |
4.0% |
| Coronary Artery Disease |
4.0% |
| Death |
4.0% |
| Drug Hypersensitivity |
4.0% |
| Hypertrophic Cardiomyopathy |
4.0% |
| Immune Thrombocytopenic Purpura |
4.0% |
| Muscle Spasticity |
4.0% |
| Mycobacterial Infection |
4.0% |
| Neoplasm |
4.0% |
| No Therapeutic Response |
4.0% |
| Off Label Use |
4.0% |
| Pharyngeal Erythema |
4.0% |
| Pigmentation Disorder |
4.0% |
| Pneumonia Cytomegaloviral |
4.0% |
| Pneumonia Influenzal |
4.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.7% |
| Prophylaxis |
9.4% |
| Acute Febrile Neutrophilic Dermatosis |
5.6% |
| Bone Marrow Conditioning Regimen |
4.3% |
| Chronic Lymphocytic Leukaemia |
3.1% |
| Plasma Cell Myeloma |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.9% |
| Fistulogram |
2.5% |
| Venous Pressure Increased |
2.5% |
| Infection Prophylaxis |
2.3% |
| Premedication |
2.2% |
| Venogram |
2.0% |
| Aplastic Anaemia |
1.9% |
| Immunosuppression |
1.9% |
| Polymyositis |
1.8% |
| Hypertension |
1.7% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Mri |
1.5% |
| Drug Use For Unknown Indication |
1.4% |
| Granulomatosis With Polyangiitis |
1.4% |
|
| Sepsis |
14.5% |
| Unevaluable Event |
9.1% |
| Ventricular Tachycardia |
9.1% |
| Respiratory Failure |
7.3% |
| Pyrexia |
5.5% |
| Venoocclusive Liver Disease |
5.5% |
| Chronic Obstructive Pulmonary Disease |
3.6% |
| Neutropenia |
3.6% |
| Polymyositis |
3.6% |
| Renal Aplasia |
3.6% |
| Renal Graft Loss |
3.6% |
| Serum Sickness |
3.6% |
| Squamous Cell Carcinoma Of Lung |
3.6% |
| Thrombotic Microangiopathy |
3.6% |
| Transplant Failure |
3.6% |
| Urinary Glycosaminoglycans Increased |
3.6% |
| Urinary Tract Infection |
3.6% |
| Urosepsis |
3.6% |
| Venoocclusive Disease |
3.6% |
| Abdominal Sepsis |
1.8% |
|
